Modafinil - CellionBiomed
Alternative Names: CBM-N1Latest Information Update: 28 Jan 2025
At a glance
- Originator CellionBioMed
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants
- Mechanism of Action Small-conductance calcium-activated potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cirrhosis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Liver-Cirrhosis in South Korea (PO)
- 29 Dec 2022 Phase-I development is ongoing in South Korea (CellionBioMed pipeline, December 2022)
- 01 Apr 2022 CellionBioMed files for patent protection for CBM N1, prior to April 2022 (CellionBioMed pipeline, April 2022)